Ticagrelore Alone Post PCI
A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 5400 participants.
Also called NCT06509893
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 5,400 participants
- Registry
-
NCT06509893
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Iran
- Registry status
- Recruiting
Technical summary
Registry record NCT06509893. Randomized; triple masking; primary purpose treatment. Start 2024-08-01 (actual); primary completion 2025-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Ticagrelore Alone Post PCI
- Acronym
- TICALONE
- Condition
- Coronary Artery Disease
- Intervention (Drug)
- aspirin 80 mg and clopidogrel 75 mg daily
- Intervention (Drug)
- Ticagrelor 90 MG
- Lead sponsor
- Shiraz University of Medical Sciences
Record details
- Record id
cardio:ct-nct06509893- Content hash
c8acef048cfa7ac9ddc73e1e895ff1281d22c766e9cf852a8ecd7100a261c983